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Abstract 
Various approaches to increase efficiency of antitumor therapy by a combination of 
vaccinotherapy, chemotherapy and surgical excision of primary tumor nodes, and also the 
comparative analyses of therapeutic and preventive application of antitumoral vaccines were 
carried out in melanoma experimental model. It was postulated that preventive vaccination is 
able to prevent tumor incidence by 70 %. The combination of vaccinotherapy and surgical 
treatment of melanoma increases antimetastatic activity of vaccination by 43 %. We conclude 
the combined therapy would lead to more effective antitumor response. 
Key words: melanoma, antitumor cell-whole GM-CSF-producing vaccine, combine therapy. 
INTRODACTION 
Presently in clinical practice tumor immunotherapy methods are actively developed and 
implemented, in particular vaccinotherapy [1,5,7]. Applying inactivated tumor cells to patients 
can be compared to applying tumor antigens because it is believed that after injection tumor cells 
will be absorbed by antigen-presenting cells (APC), processed and presented as antigen peptides 
associated with MHC molecules. Presently investigations are performed worldwide on using 
antitumor vaccines produced from tumor cells [1,7]. For improving the immune response, tumor 
cells are transfected by the gene encoding a cytokine. GM-CSF gene is the most active [1,3,7]. 
The key factor stipulating that GM-CSF-producing vaccines are more immunogenic, is the 
ability of this cytokine to induce differentiation of earlier predecessor cells in to the most 
effective “professional” APC – dendrite cells. Under the influence of GM-CSF there are 
increased levels of IL-1 and TNF production by macrophages and thus local inflammation 
reaction develops and macrophages are activated, granulocytes and NK, NKT cells are 
additionally attracted to the injection area [8]. The results of clinical applications of GM-CSF-
producing vaccines produced from transfected autologic tumor cells of patients proved that 
therapy is effective for treatment of human cancer [12]. Positive clinical effects were noted in 
25-30% patients with melanoma at stages 3-4, that were irresponsive to other chemical therapies 
employed previously. At the same time antitumor vaccination alone proved to be not as affective 
for cancer therapy [7,9,10]. 
In order to increase the effectiveness of vaccinotherapy different immunotherapy modes 
and methods are employed in appropriate experimental in vivo models [6,10,15]. 
The application of present day combined chemical therapy allowed to increase treatment 
efficacy, but survival rates remained unchanged [11]. Introducing immunotherapy methods in the 
combined therapy contributes to increasing the length of remissions without supporting therapy. 
Such drugs as cyclophosphamide, doxorubicin can significantly improve antitumor 
immunization effect [9,14]. It is based firstly on the ability of a number a chemotherapy drugs to 
suppress T-regulatory cells, the withdrawal of which increases response to many antigens 
including those of tumor origin. 
Immunotherapy by GM-CSF-producing vaccine in combination with cyclophosphamide 
and doxorubicin has been employed clinically since 2003 [10,13]. 
Stable remission after surgical treatment of initial tumor node at early stages can be 
achieved in 80-90% patients.  On the other hand, standard surgical removal of local invasive skin 
melanoma does not guarantee a long disease-free period without relapse (the absence of local 
exacerbation and distant metastasis). 
For late stages of the disease, usually, it is necessary to combine different kinds of 
therapy, i.e. immunotherapy, chemical therapy and surgical treatment [2]. 
The aim of this research is to study various methods of increasing tumor therapy 
effectiveness by means of combining vaccinotherapy, chemical therapy and surgical removal of 
initial tumor nodes using the experimental melanoma models as well as to comparatively analyze 
therapeutic and prophylactic usage of antitumor vaccination. 
 
 
MATERIALS AND METHODS. 
The experiments were carried out on C57Bl6 male mice, 22-25 gram in weight; mice 
were obtained from Animal Center (Russian Cancer Research Center, Moscow, Russia). 
Animals were treated according to the ethical guidelines of the Animal Centre, Russian Cancer 
Research Centre, Moscow, Russia. These mice were subcutaneously inoculated with melanoma 
cells. 
B16F10 mice melanoma cells were used, which are similar in their immune-phenotype to 
human melanoma model. Cultured tumors were measured twice a week, the tumor volume being 
calculated according to the next formula: 
V=DmaxxD1x(Dmax/2), where  
Dmax is maximum tumor diameter, 
D1 is diameter perpendicular to the maximum one. 
The cells express a number of tumor specific antigens and particularly express low levels or none 
of the MHC. For the vaccinotherapy BG melanoma B16F10 GM-CSF-producing clones were used. 
They were exposed to γ-rays by Agat-R using 60Co at the experimental therapy clinic of the N.N. 
Blokhin Russian Cancer Research Center. The irradiation dose was 100 gray.   
Antitumor effect was evaluated based on by tumour growth retardation and mice survival 
dynamics. Antimetastatic effects were evaluated by weight and metastatic colony number in 
lungs according to standard techniques. Surgical operations were performed using gexanal 
anesthesia (100 mg/kg one time intra abdominal).  
RESALTS AND DISCUSSIONS. 
With employment of prophylactic vaccination as a monotherapeutic approach, with the 
following transplantation of B16F10 cells in to mice, an increase in survivability was shown up 
to 50,3±3,0 days (p<0,05) in comparison with the control group (29,7±4,0), 70% of mice in this 
group did not show significant increase in the development of tumors. The vaccine was injected 
in to animals seven days before the tumor transplantation. 
In order to induce tumors mice were transplanted subcutaneously with 105 B16F10 cells.  
During the vaccination every mouse was injected subcutaneously with 1x106 of antitumor whole 
cell GM-CSF-producing vaccine. 
The dynamics of tumor growth in a typical experiment is shown in table 1. 
Table 1. Frequency of tumor growth development against the total number of mice 
in the group. 
Time  (days) Control group Prophylactic vaccination group 
7 day 3(7) 2(7) 
9 day 6(7) 2(7) 
11 day 7(7) 6(7) 
14 day 7(7) 4(7) 
18 day 7(7) 4(7) 
22 day 6(6) 5(7) 
25 day 6(6) 3(7) 
29 day 5 (5) 2(7) 
32 day 3(3) 2(6) 
37 day - 2(6) 
45 day - 1(5) 
52 day - 1(5) 
In the course of experiments appearance of infiltrates was noted at the place of injection, 
which disappeared by the end of the experiments. This process reflects the induction of the 
immune reaction at the place of injection, which can be described as delayed-type 
hypersensitivity reaction, and degree of its expression [4]. 
For treatment of developed tumors, vaccinotherapy as a monotherapy did not have any 
positive effect against the tumor growth or antimetastatic effect.  
Interestingly, minor stimulation of tumor growth was noted. At the same time, we cannot 
rule out that in this case we deal with a “false” stimulation of tumor growth, associated with 
infiltration of the tumors with immune cells and stroma cells proliferating in tumor growth zone. 
This statement is supported by the data provided in table 2, which shows the same life-
span for the control group and the group that has received vaccination. 
Table 2. Therapeutic vaccinotherapy influence on subcutaneous melanoma B16F10 
growth. 
Influence 
Overage 
life-time 
(days) 
 Life-time 
increasing 
(%) 
Overage 
tumor 
mass (gr) 
Tumor growth 
retarding (%) 
Overage 
lungs mass 
(mg) 
Metastatic 
process 
retarding (%) 
Control 
group 23,6±3,0 - 6,1±0,8 - 209,4±20,5 - 
Vaccination 
group 24,1±3,5 2 11 ±1,9 (+) 80 194,3±35,3 7 (2,0÷12,0) 
During the combined application of cytostatics, such as  Cyclophosphamide, Cisplatinum, 
Doxorubicin, Lisomustine (in high and low therapeutic doses) and antitumor cell-whole GM-
CSF-producing vaccine, no improvement in therapeutic effect against initial tumor node was 
recorded.  However,  increasing life-span of mice with melanoma B16F10 was noticed. The most 
effective type of combined therapy was using Cyclophosphamide in dose 30 mg/kg once a day 
during 5 days before and 5 days after vaccination. The dynamics of tumor growth suppression 
that developed in a typical experiment using Cyclophosphamide in dose 30 mg/kg is shown in 
fig. 1. 
Application of complex therapy of vaccination and CPh was shown to inhibit tumor 
growth by more than 90%. By 25 day of the experiment (by the time of death of the control 
untreated mice) tumor growth suppression was 73%. Control animals have lived for 24,9±1,2 
days, but complex treated animals have lived 37,0±5,1 days (p<0,05). Life-span increase was 
49%, 95% CI (39,2÷58,8). Besides cytotoxic effects on tumor cells CPh has immune correcting 
effect. It is expressed by significant improvement of antitumor effects of the vaccinotherapy. 
Fig. 1. Tumor growth retarding using combine therapy: vaccinotherapy and 
Cyclophosphamide (CPh) for a long time. 
 
The vaccinotherapy also inhibited metastatic process of melanoma B16F10 by 29-43% 
using surgical excision of the initial tumor node (for various schedules of vaccination). 
The most effective was schedule of vaccination before and after the surgical excision of  
the initial tumor node. 
For biotherapy every mouse was injected with 1x106 antitumor cell-whole GM-CSF-
producing vaccine cells subcutaneously. 
For treatment of different animal groups, vaccination was performed prior (5 days before 
surgical excision of the initial tumor node), after (5 days after surgical excision of the initial 
tumor node), and prior/after the surgical excision of the initial tumor node (the same terms). 
Tumor metastization intensity was lower in vaccinated mice(down to 20-30%), than in the 
control group. The comparative analysis of vaccine antimetastatic activity using different 
surgical excisions of the initial tumor node schedules is presented in fig. 2. 
Fig. 2. The antitumor cell-whole GM-CSF-producing vaccine antimetastatic activity 
using different surgeon excision of initial tumor node regimens. 
 
CONCLUTION. 
1. It is useful and reasonable to combine various kinds of antitumor therapy for better 
therapeutic effets on  tumor grouth. 
2. It is shown that it is possible to use too kinds of antitumor agents: antitumor whole-cell 
GM-CSF-producing vaccine and cytostatics, such as Cyclophosphamide. As a result of 
the effectiveness of these therapeutic methods and their combines application it is 
possible expand the therapeutic possibilities on antitumor therapy. 
3. Surgical treatment of the initial tumor node combined with vaccination twice produces an 
evident antimetastatic affect. Such results give the basis for optimization of vaccine 
therapy in clinical practice. 
4. High prophylactic effectiveness of antitumor whole-cell GM-CSF-producing vaccine is 
an experimental ground for development of approaches to vaccination of melanoma 
patients. 
The researches was fulfilled under financial support of Moscow Government in the 
framework of scientific and technical program “Development and implementation in 
medical practice new methods and ways of diagnostics and treatment of oncological and 
other diseases”.   
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